NBP Stock — NovaBridge Biosciences

NovaBridge Biosciences (NBP)

Updated October 16, 2026.

NBP is a Stock. Total return is -89.9% over the past 6.7 years, 242.8 points behind SPY at 152.9%.

NovaBridge Biosciences is a biotechnology company focused on developing immuno-oncology agents for cancer treatment, operating through Oncology and Ophthalmology segments. Its pipeline includes givastomig, a bispecific antibody in Phase 2 trials for gastric cancer; VIS-101, a bispecific biologic in Phase 2 development for wet age-related macular degeneration and diabetic macular edema; and ragistomag in Phase 1 trials, supported by collaborations with Bristol Myers Squibb and other partners. The company does not currently distribute to shareholders.

NBP performance versus SPY

Price and return data through 2026-10-16.

Total return is -89.9% over the past 6.7 years, 242.8 points behind SPY at 152.9%. Over the past year its total return — price change plus distributions reinvested — is -80.8%. Its deepest 1-year drawdown was 80.8%.

NBP key facts

Asset type

Stock

Asset class

Equity

Inception date

01/17/2020

Distribution frequency

None

Last close

$1.26 (as of 2026-10-16)

Market cap

$146,159,011

Average volume

350686.0

Beta

1.596

Payout ratio

0.0%

Forward P/E

2.6838

EPS

$-0.69

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

NBP risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 80.8%.

Who may consider NBP — and who may not

It is a weaker fit for investors who need monthly cash flow (NBP does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on NBP

• All tickers starting with N

Tagged: Healthcare.

Frequently asked questions